Iran Turmoil: Markets Dive, Oil Soars!
Iran War Day 11 Shaft-Stir: Oil Hits $85+, Futures Fucked – Biotech Ejaculations, China Profit Puke, Permian Prick-Tease!
Markets gagging on another Iran escalation fart—Dow futures -0.6% at 47,800, S&P -0.4% to 6,820, Nasdaq -0.5% while WTI crude rams $85.50/barrel (+1.2%) on Hormuz tanker jitters and supply choke fantasies.[1][2] Premarket's biotech cum-shot central (DAWN +65%!), e-comm earnings clusterfuck, oil wildmen humping war headlines—but dilution dong-slaps and guidance gut-punches incoming. Three nut-cracking brawls: bulls nut-tapping, bears ball-busting, my no-bullshit first-principles dong dissecting the dick-measuring.[3][4]
1) Day One Biopharmaceuticals (DAWN): “Pediatric Cancer Pipeline Penis-Pump” vs “Nasdaq Delisting Dry-Hump Disaster”
Why it’s loud
DAWN exploding +65% pre to $21.50 on reverse split news for Nasdaq compliance ($0.10 bid rule) plus positive analyst mentions and 2026 catalysts whispers—short squeeze or real juice?[5][3][6]
Bull case (Ojemda orphan drug orgasm)
Tumarkafusp (Ojemda) sales ramping for rare kid cancers, $100M+ peak potential; 2026 trials/data = multi-bagger biotech lotto, reverse split cleans slate for institutional dong-in.[7][8]
Bear case (cash-burn biotech black hole)
Reverse splits scream desperation, history of dilution diarrhea; pipeline vaporware, no profits, Iran? Who cares—biotechs bleed red forever.[5]
My take, first principles (rare disease moat vs dilution douche)
Peel the foreskin: DAWN's orphan exclusivity = pricing power goldmine in underserved pediatric DIPG/DMGs, compliance fix unlocks funding. War irrelevant. Buy the rip $20-21, $25/$30 calls trial pops—puts $18 if burn bites. Risk: Data flops.[7]
2) JD.com (JD): “China E-Comm Resilience Rimjob” vs “Subsidy Taper Tantrum Titty-Twist”
Why it’s loud
JD whipping +5% pre to $45 post-Q4 FY25: rev RMB352B (+2% YoY) beat low est but profits cratered (GAAP NI/ADS down big), buybacks announced—retail "extremely bullish" despite China slump.[9][10][11]
Bull case (logistics moat money-shot)
Self-fulfillment edge crushes PDD/Temu, user growth +13%, RMB27B FY NI + buybacks = shareholder schwanz; trade-in subsidies fading? Efficiency surges anyway.[12][13]
Bear case (macro China cock-block)
Rev miss vibes, NI tank on subsidies/competition; Alibaba/PDD price wars = margin meat-grinder, geopolitics = export export.[14][15]
My take, first principles (supply chain fortress vs consumer cock-shrink)
Strip to basics: JD's warehouse empire = unbeatable delivery moat in deflationary China, buybacks signal confidence. Oil war? Supply chain boost. Accumulate $42-43, $48/$52 calls Q1 beats—puts $40 recession rim. Risk: Stimulus flop.[16]
3) Occidental Petroleum (OXY): “Iran Oil Gusher Gangbang” vs “Buffett Debt-Dong Debacle”
Why it’s loud
OXY drilling +4% pre to $55 as WTI >$85 on Iran tanker strikes/Hormuz hell, Buffett's fave riding Permian wave—but debt whispers amid war premium pop.[17][18][19]
Bull case (Permian cash cow creampie)
Low-cost barrels ($40s breakeven) thrive at $85+, Buffett pile-in validates; CrownRock synergies = FCF flood, war drags oil to $100.[20][21]
Bear case (geopolitical pump-and-dump prick)
War ends quick = oil plunges to $70s, $20B+ debt + Anadarko hangover = dividend dice-roll; EV shift = long-term loser.[22]
My take, first principles (Tier-1 acreage vs leverage limp-dick)
Bare the balls: OXY's Permian inventory = decade-long inventory edge, balance sheet fortified post-CrownRock. Iran inflation hedge. Scalp $53-54, $58/$62 calls escalation—puts $51 de-escalation. Risk: OPEC flood.[23]
Tape-Side Tactics (cock the hammer or blue-ball bail)
- DAWN: $20-21 squeeze thrust; $25C/$30C spreads, P$18 delist dread.[5]
- JD: $42-43 resilience ride; $48C/$52C OTM, P$40 China chill.[9]
- OXY: $53-54 oil orgy; $58/$62 calls war wet dream, P$51 peace prick.[17]
Iran clusterfuck cranking crude chaos—gusher glory or inflation ass-fuck? DYOR, don't YOLO your yogurt.